ATRA
AtaraยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ATRA Profile
Atara Biotherapeutics, Inc.
A pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for solid tumors, hematologic cancers and autoimmune disease
Biological Technology
08/22/2012
10/16/2014
NASDAQ Stock Exchange
153
12-31
Common stock
2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, CA, 91320
--
Atara Biotherapeutics, Inc., was incorporated in Delaware on August 22, 2012. The company is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop translational therapies for patients with cancer and autoimmune diseases.
